Data investigation

Less Than Half Are Still Taking It

Of 393 people prescribed semaglutide for weight loss, 44% were still taking it a year later. Those who were lost 13.8% of their weight; those who were not lost 6.4%.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

This register has spent a great deal of effort on differences of a few percentage points between drugs. Here is the number that dwarfs all of them. Of 393 people prescribed semaglutide for weight loss in one health system, 44% were still taking it a year later, and those who were lost 13.8% of their weight against 6.4% for those who were not.[1]

What was measured

Persistence was defined strictly but reasonably: no gap of more than 60 days in twelve months. Adherence used a separate standard, which required having medication on hand at least 80% of days. Both landed in the same place.

393 patients prescribed semaglutide for weight loss, followed 12 months.[1]
ProportionWeight loss at 12 months
Persistent44% (172)13.8%
Not persistent56%6.4%
Adherent (≥80% of days covered)44% (175)13.0%
Thirteen point eight percent against six point four. Nothing else on this site produces a gap that size.

The 13.8% figure matters on its own. It sits close to what the trials report, which means the drug works in ordinary care roughly as advertised for the minority who keep taking it. The gap between trial results and real-world results is largely a gap in continuation, not in pharmacology.

How you climb the ladder

Patients who closely followed the approved titration schedule lost 12.5% at twelve months. Those on other titration patterns lost 7.2%. Nearly double, from the same drug, differing only in how the dose was raised.

That is one of the few actionable findings in this whole literature, and it sits beside another. A randomized trial found that a slower, flexible titration cut withdrawal for gastrointestinal side effects from 19% to 2% while reaching similar final doses and similar results (see five clicks instead of a quarter milligram).

Taken together, erratic titration produces worse results, and deliberately slower titration keeps people on treatment without costing efficacy. How someone climbs the ladder appears to matter more than which ladder they are on, and no drug comparison would ever surface that.

One caution on direction. People who titrate irregularly may be doing so because of side effects, cost interruptions or supply gaps. If so, poor titration may be a symptom of the same problems that cause poor results rather than the cause of them. An observational cohort cannot separate those.

The finding that runs against expectation

Women had lower odds of both persistence and adherence than men, with odds ratios of 0.32 (95% CI 0.14–0.75) and 0.33 (0.14–0.77). Race, ethnicity and comorbidities showed no significant association with either.

Hold that one loosely. Those intervals run from 0.14 to 0.75 in a cohort of 393, which establishes a direction and little about the size. It is also the opposite of what this field’s framing would predict. Trials over-recruit women, and the cultural conversation about these drugs is largely about women taking them.

The study does not explain it, and neither will we. We report it because it is unexpected, and because it has since turned up again in a Scottish national cohort where women were more likely to be classified as intolerant specifically: not taking it and not tolerating it. Different country, different measure, same direction.

What it means for reading everything else

Almost every comparison on this register assumes the person is taking the drug: 6.5 percentage points for adding cagrilintide, 6.5 for tirzepatide over semaglutide, 3.1 for tripling a dose, 0.75 of an HbA1c point against a competitor. In this cohort, most did not stay on it consistently through the year.

  • Tolerability outranks efficacy in determining outcome, because a drug someone stops delivers nothing.
  • Cost and coverage are clinical variables, not administrative ones, and this cohort spans 2021–2024, a period of shortages and shifting coverage. That is part of what “persistence” is measuring here.
  • The first year is when support matters most. That is the authors’ own recommendation.
  • It is one health system and 393 people. Persistence figures vary widely by setting, insurance and country.

If the odds say you may stop or pause at some point, read the exit terms before the first charge. DreamHug Medical sells one-time purchases that never renew, so there is nothing to cancel, and Cielo lets you cancel anytime and says you owe only for medication already shipped. MyFastRx also lets you cancel anytime, and refunds an unfinished prepaid plan after repricing the months you received at the shorter-plan rate. Claya needs at least two days’ notice before billing or charges one more cycle, and MultiMedRx bills in four-week cycles and takes cancellations by email.

Refund terms vary just as much. Regenics lets you cancel anytime but refunds nothing, membership fees included, while Medivive and EverFit Medical treat consultation fees as final once a provider has reviewed you. Lyfe Rx lets you cancel anytime and has no early termination fee, but every sale is final once a prescription is filled or shipped; canceling before the fill refunds the order minus a consultation fee.

For what happens to weight after people stop, see what happens when you stop; for what those who stopped did next, what people actually do after stopping.

Frequently Asked Questions

In this cohort of 393 patients in one health system, 44% were persistent, meaning no gap of more than 60 days across twelve months. The same proportion met the separate standard for adherence.
For those who stayed on it, yes: 13.8% weight loss at twelve months, close to trial figures. Those who did not stay on it lost 6.4%. The gap between trials and real life is largely about continuation rather than pharmacology.
Substantially. Patients closely following the approved schedule lost 12.5% at twelve months against 7.2% for other patterns, nearly double. Irregular titration may also be a symptom of side effects or supply gaps rather than a cause of poor results.
In this cohort, yes, with odds ratios of 0.32 for persistence and 0.33 for adherence compared with men. The confidence intervals are wide, the study does not explain it, and it runs opposite to how this field is usually framed.
That whether you are still taking the drug in a year matters more than which drug it is. Every comparison between these medicines is smaller than the difference between continuing and stopping.

References

  1. 1.Baalmann A, Michel J, Avedissian SN, et al. Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system Journal of Managed Care & Specialty Pharmacy. 2026. PMID: 42166306.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.8

altRX

Compounded semaglutide from $89/month at the same price at every dose

9.0

CoreAge Rx

Flat-priced compounded semaglutide at $79 a month, any dose

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →